Category Archives: Actos

Featured Stories
FDA Questions Device Makers about Duodenoscope Cleaning Procedures

Following Deadly Outbreaks, FDA Questions Device Makers about Duodenoscope Cleaning Procedures

In light of a recent outbreak linked to contaminated duodenoscopes, the U.S. Food and Drug Administration (FDA) is questioning manufacturers about their methods for cleaning the devices, the New York Times reports. The specialized scopes, which have been linked to several outbreaks in recent years, most recently infected seven patients ...

Read More

Canadian Warning Issued for Actos Bladder Cancer Side Effect Risk

Health Canada has become the most recent national drug regulator to issue a warning about Actos and bladder cancer. Last month, the agency warned that interim results from a 10-year-study indicated that patients taking Actos for more than a year faced an increased risk of bladder cancer. Health Canada also ...

Read More

Long Island Car Crash Kills 1 Person, Injures 2 More

Long Island Car Crash Kills 1 Person, Injures 2 More

A car accident on LI left one person dead & two more critically injured. The crash occurred Monday in Deer Park on Straight Path, south of Sagamore Lane.

Read More

Canadian Study Confirms Actos Bladder Cancer Risk

A new study conducted by Canadian researchers has found that users of the type 2 diabetes drug, Actos (pioglitazone), may face a higher risk of developing bladder cancer than first thought. The study, published in the British Medical Journal, found that taking Actos for two years doubles the likelihood ...

Read More

Cancer Groups Call for E-cigarettes Regulation/Research

Two Leading Cancer Groups Issue Call for Regulation of E-cigarettes and Research on Health Risks

In a joint statement, the American Society of Clinical Oncology and the American Association for Cancer Research have called on the federal government to move quickly to regulate e-cigarettes and increase research on their health effects. These leading research and treatment organizations asked the Food and Drug Administration (FDA) to make ...

Read More

Majority of Metal-on-Metal Hip Implant Failures Occur within Two Years, Study Finds

A newly published metal-on-metal hip replacement study is reporting that the majority of failures occur early, within two years of surgery. The study, published in the journal Orthopedics, is just the latest to indicate that close follow-up of metal-on-metal hip implant patients is warranted.

Read More

Actos Bladder Cancer Lawsuit Filed by West Virginia Resident

Actos (pioglitazone) continues to be named in lawsuits alleging long-term use of the type 2 diabetes drug caused patients to develop bladder cancer. Just last week, the national law firm of Parker Waichman LLP filed suit against Takeda Pharmaceuticals on behalf of a West Virginia man who developed bladder cancer ...

Read More

FDA Urged to Ban Powdered Caffeine

FDA Urged to Ban Powdered Caffeine

Pennsylvania Senator Robert Casey has written to the Food and Drug Administration (FDA) to urge the agency to ban powdered caffeine, a dietary supplement.

Read More

Toxic Nano-Particles from Failing Metal-on-Metal Hip Replacements May Pose Long-Term Health Risks

According to a new study, failing metal-on-metal hip implants generate toxic nano-particles that release Cobalt 2+ ions, which not only cause inflammation in surrounding tissue, but have the potential to cause long-term damage to the genetic material of cells. According to a report published by Medicalxpress.com, this “genotoxicity” could ...

Read More

Stryker Metal Hip Implant Component Recall Bad News for Makers of Metal-on-Metal Hip Replacement Devices

Stryker’s recent recall of two metal hip implant components, the Rejuvenate Modular and ABG II modular-neck hip stems, may have dealt a serious blow to one of the key arguments medical device manufacturers have made to defend their metal-on-metal hip replacements. Facing thousands of lawsuits, the makers of ...

Read More

Controversial Diabetes Drug Actos Still on the Market

Controversial Diabetes Drug Actos Still on the Market

Though research has shown an association between the type 2 diabetes drug Actos and serious side effects including bladder cancer, heart failure, liver failure, and bone fractures, the Food and Drug Administration (FDA) has stopped short of recalling Actos. Actos … Continue reading

Posted in Actos, Pharmaceuticals | Tagged , , , , |

Actos Makers Continue to Face Bladder Cancer Claims

Actos Makers Continue to Face Bladder Cancer Claims

Lawsuits continue to be filed over Actos, a type 2 diabetes drug developed by Takeda and Eli Lilly. Plaintiffs in the litigation allege that Actos contributed to bladder cancer. Drug makers are accused of failing to disclose this risk to … Continue reading

Posted in Actos, Pharmaceuticals | Tagged , , , , |

Actos Bladder Cancer Cases Continue to be Filed

In the continuing controversy over the link between the type 2 diabetes drug Actos (pioglitazone) and bladder cancer, a new lawsuit was filed in June 2016 by a man who was diagnosed with bladder cancer after taking Actos for six … Continue reading

Posted in Actos, Defective Products, Health Concerns, Pharmaceuticals |

Diabetes Drug Pioglitazone Linked to Increased Risk of Bladder Cancer

An increased risk of bladder cancer has been uncovered following a large population-based study concerning patients who take the diabetes drug pioglitazone known to most as Actos, the Renal and Urology News reports. Pioglitazone is a single-ingredient product sold under … Continue reading

Posted in Actos, Health Concerns, Pharmaceuticals |

$2.4 Billion Settlement Announced in Actos Bladder Cancer Cases

$2.4B Settlement Announced in Actos Bladder Cancer Cases

On Tuesday, Takeda Pharmaceuticals announced a settlement that could go as high as $2.7 billion to resolve thousands of lawsuits from patients and their families who claim the diabetes drug Actos (pioglitazone) caused their bladder cancer. The New York Times … Continue reading

Posted in Actos, Health Concerns, Legal News, Pharmaceuticals | Tagged , , , |

Jury Awards $2 Million in Actos Case

Late last week, a Pennsylvania jury ordered Takeda Pharmaceuticals to pay more than $2 million to a woman who claimed her bladder cancer was caused by the company’s diabetes drug Actos (pioglitazone). The jury found that Takeda officials failed to … Continue reading

Posted in Actos, Legal News, Pharmaceuticals |

Actos Litigation Update: Takeda Pharmaceutical Company, Eli Lilly and Company Ordered to Pay $9 Billion in Punitive Damages

Takeda Pharmaceutical Company and Eli Lilly and Company were just ordered to pay a total of $9 billion in punitive damages over Actos litigation involving bladder cancer allegations. Takeda and Eli Lilly lost a bid to have the Actos trial … Continue reading

Posted in Actos, Pharmaceuticals |

Jury Deliberations Begin in Nevada Actos Trial

On Tuesday, a jury in the Las Vegas began deliberating to determine whether Takeda Pharmaceuticals is liable for the bladder cancer of two women, both in their 80s, who were diagnosed with the disease after taking the diabetes drug Actos … Continue reading

Posted in Actos, Health Concerns, Legal News, Pharmaceuticals |

Judge May Punish Lawyers for Misconduct in Actos Trial

Las Vegas district judge Kerry Earley is considering a request to punish lawyers for misconduct during a civil trial over the cancer risks associated with Takeda Pharmaceuticals’ diabetes drug Actos. On Thursday, Judge Earley heard arguments from an attorney representing … Continue reading

Posted in Actos, Health Concerns, Legal News, Pharmaceuticals |

Takeda May Not Pay Eli Lilly’s Portion of Actos Injury Lawsuit

Eli Lilly & Co. has indicated that its former marketing partner, Takeda Pharmaceutical Co., may not pay Lilly’s share of a recent United States jury verdict that ordered Takeda and Lilly to pay $9 billion in punitive damages in a … Continue reading

Posted in Actos, Legal News, Pharmaceuticals |

© 2005-2018 Parker Waichman LLP ®. All Rights Reserved.